Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck.
Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck.
复制标题
DOI：
10.1002/hed.20898
复制
发表时间：
2009-03
影响因子：
2.9
通讯作者：
Lustig, Robert A.
中科院分区：
文献类型：
--
作者：
Shinohara, Eric T.;Maity, Amit;Jha, Neha;Lustig, Robert A.
据估计，2007年将诊断出34,000例头颈部鳞状细胞癌（HNSCC），估计死亡人数为7,500人。放疗通常用于治疗这些病人。临床前研究表明西罗莫司可能是一种有效的HNSCC放射增敏剂。本病例报告描述了一个病人，状态后肝移植，谁是切换到西罗莫司免疫抑制。患者随后接受了喉部T2N0M0鳞状细胞癌的放射治疗。患者对放射治疗有不同寻常的早期反应，在七次放射治疗后临床完全缓解。然而，患者也比预期的更早出现毒性，并且在11分后需要中断辐射。据作者所知，这是第一个表明西罗莫司是HNSCC患者有效的放射增敏剂的观察结果。我们希望我们的结果能引起人们对未来临床研究的兴趣。
An estimated 34,000 cases of squamous cell carcinomas of the head and neck (HNSCC) will be diagnosed in 2007 with 7,500 estimated deaths. Radiation is commonly used to treat these patients. Preclinical studies have suggested that sirolimus may be an effective radiosensitizer in HNSCC. The present case report describes a patient, status post liver transplant, who was switched to sirolimus for immunosupression. The patient subsequently underwent radiation therapy for a T2N0M0 SCC of the larynx. The patient had an unusually early response to radiation, with a clinical complete response after seven fractions of radiation. However, the patients also had toxicity earlier than expected and required a break from radiation after eleven fractions. To the authors’ knowledge, this is the first observation to suggest that sirolimus is an effective radiosensitizer in patients with HNSCC. We hope that our results will create interest in future clinical studies.
登录
查看更多内容
影响因子：
45.3
作者：
Chan, S;Scheulen, ME;Moore, L
通讯作者：
Moore, L
影响因子：
45.3
作者：
Atkins, MB;Hidalgo, M;Sherman, ML
通讯作者：
Sherman, ML
影响因子：
6.2
作者：
Margolin, K;Longmate, J;Doroshow, JH
通讯作者：
Doroshow, JH
影响因子：
45.3
作者：
Raymond, E;Alexandre, J;Armand, JP
通讯作者：
Armand, JP
影响因子：
2.6
作者：
Nathan, CAO;Amirghahri, N;Stucker, FJ
通讯作者：
Stucker, FJ